Dr. Reddy’s Laboratories announces first-to-market launch of Carboprost Tromethamine Injection USP, 250 mcg/mL (1mL)Single-dose Vial in the U.S. Market

Hyderabad, July 04, 2019: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Carboprost Tromethamine Injection USP,250 mcg/mL (1mL)Single-dose Vial,a therapeutic equivalent generic version of Hemabate®injection,  250 mcg/mL,approved by the U.S. Food and Drug Administration (USFDA).

“We are pleased to be first-to-market with this product that has been designated as a Competitive Generic Therapy (CGT) by the FDA,” says Marc Kikuchi, Chief Executive Officer, North America Generics, Dr. Reddy’s Laboratories. “With a CGT designation, we have 180-day CGT exclusivity to market this product.”

The Hemabate® injection, 250 mcg/mL brand had U.S. sales of approximately $55 million MAT for the most recent twelve months ending in April 2019 according to IQVIA Health*.

Dr. Reddy’s CarboprostTromethamine Injection USP, 250mcg/mL (1mL)containscarboprosttromethamine equivalent to 250 mcg of carboprost.

Corporate Comm India(CCI Newswire)